Article
Multidisciplinary Sciences
Kangsan Kim, Qinbo Zhou, Alana Christie, Christina Stevens, Yuanqing Ma, Oreoluwa Onabolu, Suneetha Chintalapati, Tiffani Mckenzie, Vanina Toffessi Tcheuyap, Layton Woolford, He Zhang, Nirmish Singla, Pravat Kumar Parida, Mauricio Marquez-Palencia, Ivan Pedrosa, Vitaly Margulis, Arthur Sagalowsky, Zhiqun Xie, Tao Wang, Steffen Durinck, Zora Modrusan, Somasekar Seshagiri, Payal Kapur, James Brugarolas, Srinivas Malladi
Summary: In this study, the authors explore the determinants of vascular invasion and metastasis in RCC patients with tumor thrombi (TT). They found that tumor thrombi associated with metastases are characterized by higher grade, mTOR activation, and a particular immune contexture. TT grade is a better predictor of metastasis than overall tumor grade.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Chester Kao, Daniel J. George, Tian Zhang
Summary: The case demonstrates the potential of combination cabozantinib plus nivolumab therapy in salvaging disease control in refractory metastatic renal cell carcinoma, and highlights the potential efficacy of vascular endothelial growth factor inhibitors and immune checkpoint inhibitors combination therapy.
Article
Oncology
Josiah An, Vignesh T. Packiam, Adithya Chennamadhavuni, Jordan Richards, Jayanshu Jain, Sarah L. Mott, Rohan Garje
Summary: This study assessed the incidence and survival outcomes of non-clear cell renal cell carcinoma (ccRCC) subtypes compared to ccRCC. The results showed that the survival rate was not significantly different between papillary RCC and ccRCC, while collecting duct and sarcomatoid subtypes had poorer survival outcomes. Further studies are needed to evaluate the role of neoadjuvant and adjuvant systemic therapies in improving oncologic outcomes for these subtypes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Luis Meza, Matthew Feng, Kyle Lee, Rubens Sperandio, Sumanta Kumar Pal
Summary: The introduction of targeted therapy and immuno-oncology has revolutionized the treatment of metastatic renal cell carcinoma. However, a significant percentage of patients still experience progressive disease despite these advancements. Evidence suggests that the gut microbiome could serve as a biomarker for treatment response and have potential implications in increasing response to these therapies. This review provides an overview of the role of the gut microbiome in cancer and its potential significance in the treatment of metastatic renal cell carcinoma.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Urology & Nephrology
V Gruenwald, L. Bergmann, B. Brehmer, B. Eberhardt, Karin Kastrati, T. Gauler, G. Gehbauer, J. Gschwend, M. Johannsen, T. Klotz, C. Protzel, M. Schenck, M. Staehler
Summary: The treatment landscape in metastatic renal cell carcinoma (mRCC) has undergone significant changes in recent years. The German RCC guideline committee has evaluated current medical treatments and provided recommendations. Combination therapy with immune checkpoint inhibitors (ICI) is strongly recommended as the first-line standard of care, but there is currently no clear standard for subsequent treatment after ICI failure.
WORLD JOURNAL OF UROLOGY
(2022)
Article
Multidisciplinary Sciences
Adele M. Alchahin, Shenglin Mei, Ioanna Tsea, Taghreed Hirz, Youmna Kfoury, Douglas Dahl, Chin-Lee Wu, Alexander O. Subtelny, Shulin Wu, David T. Scadden, John H. Shin, Philip J. Saylor, David B. Sykes, Peter V. Kharchenko, Ninib Baryawno
Summary: By analyzing ccRCC patient samples using single-cell transcriptomics, a distinct transcriptional signature predictive of metastatic potential and patient survival was identified. Potential therapeutic targets including the CXCL9/CXCL10-CXCR3 axis and the CD70-CD27 axis were highlighted.
NATURE COMMUNICATIONS
(2022)
Review
Medicine, General & Internal
Marc-Oliver Grimm, Katharina Leucht, Susan Foller
Summary: Systemic therapy for metastatic renal cell carcinoma has evolved over the past two decades, with significant improvements in survival and quality of life seen in advanced patients. Treatment options have shifted towards combination therapies with PD(L)-1 immune checkpoint inhibitors, as well as VEGFR-TKI/ICI combinations. Risk stratification using IMDC criteria and detailed patient counseling on treatment efficacy and potential side effects are crucial in individual treatment decisions.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Kevin K. Zarrabi, Oladimeji Lanade, Daniel M. Geynisman
Summary: Kidney cancer is a common type of cancer, with clear cell renal cell carcinoma being the most frequent form. Treatment options for newly diagnosed metastatic clear cell renal cell carcinoma include surgery, radiation, and systemic therapies. The complexity of treatment selection has increased due to the diverse biology of tumors. The therapeutic landscape for metastatic renal cell carcinoma has rapidly evolved, with combination therapy strategies involving immune checkpoint blockade and anti-angiogenesis targeted therapy becoming the standard of care.
Editorial Material
Urology & Nephrology
Matthew S. Ernst, Vishal Navani, J. Connor Wells, Frede Donskov, Naveen Basappa, Chris Labaki, Sumanta K. Pal, Luis Meza, Lori A. Wood, D. Scott Ernst, Bernadett Szabados, Rana R. McKay, Francis Parnis, Cristina Suarez, Takeshi Yuasa, Aly-Khan Lalani, Ajjai Alva, Georg A. Bjarnason, Toni K. Choueiri, Daniel Y. C. Heng
Summary: This study establishes real-world clinical benchmarks for immune-oncology (IO) and vascular endothelial growth factor targeted therapies (VEGF-TT) combination treatments in metastatic renal cell carcinoma (mRCC) patients, based on the International mRCC Database Consortium (IMDC) criteria.
Review
Oncology
San Hue Hua, Maximillian Viera, George W. Yip, Boon Huat Bay
Summary: Glycosaminoglycans (GAGs) are a class of carbohydrates closely associated with cancer progression. They play important roles in cancer cell growth and signaling, as well as cell migration and invasion, which are crucial for metastasis. This review explores the potential use of GAGs as biomarkers and therapeutic targets for metastatic renal cancer, a disease with poor survival rates and major treatment challenges.
Review
Oncology
Joseph A. Vento, Brian Rini
Summary: The treatment of refractory renal cell carcinoma is constantly evolving. Combination therapies of immune checkpoint inhibitors and targeted tyrosine kinase inhibitors have shown improvement in first-line treatment. However, some patients do not respond to these treatments, necessitating the search for effective options. This review explores the current treatment options, ongoing trials, and considerations for non-clear cell histologies in refractory renal cell carcinoma.
Article
Oncology
Jonathan Thouvenin, Omar Alhalabi, Maria Carlo, Lucia Carril-Ajuria, Laure Hirsch, Nieves Martinez-Chanza, Sylvie Negrier, Luca Campedel, Dylan Martini, Delphine Borchiellini, Jad Chahoud, Massimo Lodi, Philippe Barthelemy, Elshad Hasanov, Andrew W. Hahn, Thierry Gil, Srinivas R. Viswanathan, Ziad Bakouny, Pavlos Msaouel, Mehmet Asim Bilen, Toni K. Choueiri, Laurence Albiges, Nizar M. Tannir, Gabriel G. Malouf
Summary: This study provides evidence of the activity of cabozantinib in TRCC, with more durable responses than those observed historically with other VEGFR-TKIs or ICIs.
Article
Oncology
Gennady Bratslavsky, Stephanie Gleicher, Joseph M. Jacob, Thomas H. Sanford, Oleg Shapiro, Dimitra Bourboulia, Laurie M. Gay, Julie Andrea Elvin, Jo-Anne Vergilio, James Suh, Shakti Ramkissoon, Eric Allan Severson, Jonathan Keith Killian, Alexa Betzig Schrock, Jon H. Chung, Vincent A. Miller, Mehdi Mollapour, Jeffrey S. Ross
Summary: The study found that genomic alteration patterns in collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) differ significantly from clear cell renal cell carcinoma (CCRCC). Targeted therapies for CDC and RMC appear limited, with rare opportunities to target alterations in receptor tyrosine kinase and MTOR pathways. Similarly, the low TMB and absence of MSI-High status in CDC and RMC suggest resistance to immunotherapies.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Oncology
Matthew Bootsma, Rana R. McKay, Hamid Emamekhoo, Rory M. Bade, Jennifer L. Schehr, Matthew C. Mannino, Anupama Singh, Serena K. Wolfe, Zachery D. Schultz, Jamie Sperger, Wanling Xie, Sabina Signoretti, Christos E. Kyriakopoulos, David Kosoff, Edwin J. Abel, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Michael Bassetti, John Floberg, Menggang Yu, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Toni K. Choueiri, Joshua M. Lang, Shuang G. Zhao
Summary: In this study, liquid biopsies were used to analyze CTC enumeration and the HLA I to PD-L1 ratio in metastatic renal cell carcinoma (mRCC) patients. The results showed that changes in CTC abundance and the HP ratio were significantly associated with treatment response and overall survival. These findings provide potential biomarkers to predict and monitor response to immunotherapy in mRCC.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Kun Meng, Shaohua Lu, Yu-Ying Li, Li-Ling Hu, Jing Zhang, Yun Cao, Yang Wang, Chris Zhiyi Zhang, Qing-Yu He
Summary: The study discovered a microprotein encoded by LINC00493, called SMIM26, which is localized in mitochondria and tends to be downregulated in ccRCC. SMIM26 suppresses ccRCC growth and metastasis by interacting with AGK and SLC25A11. This interaction increases the mitochondrial localization of AGK and inhibits AGK-mediated AKT phosphorylation. The study shows the importance of hidden proteins in human cancers.
